Get the Stockscreener App
109.60
4.15%
4.37
After Hours:
109.60
Glaukos Corporation stock is traded at $109.60, with a volume of 706.14K.
It is up +4.15% in the last 24 hours and down -9.34% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$105.23
Open:
$106.46
24h Volume:
706.14K
Relative Volume:
0.93
Market Cap:
$6.37B
Revenue:
$507.44M
Net Income/Loss:
$-187.69M
P/E Ratio:
-33.51
EPS:
-3.271
Net Cash Flow:
$-39.06M
1W Performance:
+6.18%
1M Performance:
-9.34%
6M Performance:
+34.53%
1Y Performance:
+2.52%
1-Day Range:
$105.39
$109.67
1-Week Range:
$100.15
$109.67
52-Week Range:
$73.16
$130.23
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
109.60 | 6.11B | 507.44M | -187.69M | -39.06M | -3.271 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Buy |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Insider Selling: Glaukos (NYSE:GKOS) CFO Sells 1,521 Shares of Stock - MarketBeat
Glaukos CFO Thurman sells $160k in shares - Investing.com
Glaukos (NYSE: GKOS) CDO has shares withheld to cover tax obligations - Stock Titan
Glaukos (NYSE: GKOS) CFO sale and tax share withholdings detailed - Stock Titan
Glaukos (NYSE: GKOS) insider plans sale of 2,511 vested shares - Stock Titan
Glaukos (GKOS) affiliate files to sell 1,521 shares after vesting - Stock Titan
Glaukos launches Epioxa, boosts growth in corneal treatments - MSN
Glaukos Corp Stock Faces Monthly Pressure Amid Analyst Optimism and Glaucoma Innovation Push - AD HOC NEWS
Piper Sandler reiterates Glaukos stock rating on growth outlook - Investing.com UK
Piper Sandler reiterates Glaukos stock rating on growth outlook By Investing.com - Investing.com South Africa
Why is Glaukos (GKOS) down 14.7% since last earnings report? - MSN
JPMorgan Chase & Co. Has $54.65 Million Stock Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos Introduces Epioxa, Accelerating Expansion in Corneal Therapy - Bitget
Glaukos Announces Commercial Availability of Epioxa, a Transformative Innovation in Interventional Keratoconus Care - marketscreener.com
Glaukos Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments - Yahoo Finance Singapore
Glaukos (GKOS) Launches Epioxa HD for Keratoconus Treatment - GuruFocus
Glaukos Corporation (NYSE:GKOS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Glaukos Announces Commercial Availability of Epioxa for Incision-Free Keratoconus Care - VisionMonday.com
Glaukos SVP Thurman sells $61,968 in GKOS stock By Investing.com - Investing.com India
Navratil, Glaukos corp officer, sells $101k in GKOS stock By Investing.com - Investing.com Australia
Glaukos (NYSE:GKOS) CFO Alex Thurman Sells 625 Shares - MarketBeat
Glaukos SVP Thurman sells $61,968 in GKOS stock - Investing.com
Navratil, Glaukos corp officer, sells $101k in GKOS stock - Investing.com
Glaukos (NYSE: GKOS) CDO reports 1,031-share sale and tax withholding - Stock Titan
Glaukos (NYSE: GKOS) CFO sells 625 shares under 10b5-1 plan - Stock Titan
GLAUKOS (NYSE: GKOS) COO reports tax-withholding of 1,189 vested shares - Stock Titan
[Form 4] GLAUKOS Corp Insider Trading A... - Stock Titan
Glaukos' Epioxa now commercially available in the US - Eyes On Eyecare
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care - BioSpace
Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report? - Yahoo Finance
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional - pharmiweb.com
Glaukos announces commercial availability of Epioxa for the treatment of keratoconus - Optometry Times
Glaukos Corporation Announces Commercial Availability Of Epioxa HD / Epioxa For Keratoconus Treatment - marketscreener.com
Glaukos Launches Epioxa for Keratoconus Treatment - marketscreener.com
Glaukos announces commercial availability of Epioxa HD/Epioxa - TipRanks
(GKOS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Glaukos Corporation (NYSE:GKOS) Q4 2025 earnings call transcript - MSN
Glaukos (NYSE: GKOS) CDO reports tax-withholding of 1,074 shares - Stock Titan
Glaukos (GKOS) CEO Burns reports 5,212-share tax withholding and large trust holdings - Stock Titan
[144] GLAUKOS Corp SEC Filing - Stock Titan
Glaukos Corporation $GKOS Shares Sold by Holocene Advisors LP - MarketBeat
Cinctive Capital Management LP Makes New Investment in Glaukos Corporation $GKOS - MarketBeat
Alliancebernstein L.P. Has $141.37 Million Holdings in Glaukos Corporation $GKOS - MarketBeat
SpyGlass Valued at $900M After IPO - Orange County Business Journal
Glaukos Corporation $GKOS Shares Purchased by Iron Triangle Partners LP - MarketBeat
Fred Alger Management LLC Sells 109,170 Shares of Glaukos Corporation $GKOS - MarketBeat
Truist Securities maintains Glaukos (GKOS) buy recommendation - MSN
Braidwell LP Acquires 176,750 Shares of Glaukos Corporation $GKOS - MarketBeat
GKOS Stock Falls -20% In 9-day Spree On Earnings Shock - Trefis
Integral Health Asset Management LLC Acquires 50,000 Shares of Glaukos Corporation $GKOS - MarketBeat
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):